Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (24)

I-021Enrique José Bandín Vilar

OPTIMIZATION OF THE DOSAGE REGIMEN OF LONG-ACTING INJECTABLE ARIPIPRAZOLE THROUGH MONTE CARLO SIMULATIONS

Wednesday 10:20-11:50

I-024Carla Bastida Fernández

Predictive performance of published meropenem population pharmacokinetic models in critically ill adult patients.

Wednesday 10:20-11:50

I-026Emily Behrens

External evaluation of pharmacometric models of moxifloxacin for Bayesian forecasting in the treatment of tuberculosis

Wednesday 10:20-11:50

I-031Jan Berkhout

A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration

Wednesday 10:20-11:50

I-040Jordan Brooks

Steps Toward Model-Informed Precision Dosing of PEG-Asparaginase in Children and Young Adults

Wednesday 10:20-11:50

I-104Aaqilah Fataar

Using Bayesian Modelling to Evaluate the Effect of a Neonatal Vancomycin Loading Dose on Therapeutic Target Attainment in a Low-Middle Income Country

Wednesday 10:20-11:50

II-008Janice Goh

A model-informed framework for prioritizing pharmacogenomic drug-gene interactions in an Asian context for chemotherapy

Wednesday 15:20-16:50

II-010Juan Guillermo Gonzalez Maffe

A Bayesian (P)K-TTE model to support early dose escalation decisions in phase 1 Oncology studies

Wednesday 15:20-16:50

II-032Astrid Heida

Model-informed dose optimization of mycophenolic acid in pediatric renal transplant patients

Wednesday 15:20-16:50

II-061Xu Jiang

Population pharmacokinetic and pharmacodynamic analysis of granulocyte colony-stimulating factor (G-CSF) to optimize dose and timing for harvesting CD34+ cells

Wednesday 15:20-16:50

II-074Anisa Khan

Population pharmacokinetics of cenobamate and dose rationale for its use in paediatric patients affected by focal onset and primary generalized tonic-clonic seizures.

Wednesday 15:20-16:50

II-081Sjoerd Koopman

A revised population pharmacokinetic model for recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin

Wednesday 15:20-16:50

II-099Antonia Leonhardt

Towards MIPD of Linezolid: External Evaluation of Population Pharmacokinetic Models

Wednesday 15:20-16:50

III-001Nicolas Luyckx

Model-Informed Precision Dosing of Tacrolimus in Lung Transplantation Early After Surgery Using Model-Predictive Control in the tdmore Framework

Thursday 09:50-11:20

III-005SOPHIE MAGREAULT

What clindamycin dose for which administration route in case of combination with rifampicin?

Thursday 09:50-11:20

III-046Nuo Xu

Population Pharmacokinetics and Safety Assessment of Rifapentine in Chinese Children to Inform Dosing Recommendations for Latent Tuberculosis Infection

Thursday 09:50-11:20

III-092Camille Riff

Pharmacokinetics of inhaled AZD4604 supports lack of JAK1 systemic activity at therapeutic dose

Thursday 09:50-11:20

IV-011Victor Sokolov

Quantitative Systems Pharmacology Model of Type 1 IFN-mediated Inflammation in Systemic Lupus Erythematosus

Thursday 15:00-16:30

IV-027Jérémie Tachet

Population pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study

Thursday 15:00-16:30

IV-045Quan Truong

Underdosing imipenem in patients with renal insufficiency: global clinical data-driven pharmacokinetic/pharmacodynamic study

Thursday 15:00-16:30

IV-052Stefan van den Berg

Pharmacokinetic model-informed precision dosing of natalizumab in Multiple Sclerosis

Thursday 15:00-16:30

IV-060Erno van Schaick

Population Pharmacokinetic Modeling of Leriglitazone in Healthy Volunteers and Patients with Neuro-degenerative Disorders – Exploring dosing schedules in children with adrenoleukodystrophy via simulations

Thursday 15:00-16:30

IV-082Franz Weber

Successful validation of a model-informed precision dosing instrument for meropenem in critically ill patients, the DoseCalculator, against NONMEM®

Thursday 15:00-16:30

IV-085Ella Widigson

Model-derived PK target profile of ustekinumab therapeutic thresholds in inflammatory bowel diseases to guide precision dosing

Thursday 15:00-16:30